Clinical trials in Villejuif – page 7

940 clinical trials in Villejuif, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Villejuif at a glance

940

clinical trials

Research sites2

Quick filters

940 trials in Villejuif

Open in trial search

Anaemia+1

Recruiting

A Phase 3 Study of Elritercept Versus Epoetin Alfa in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

Registered drugNo placebo

A Phase 3 Study of Elritercept Versus Epoetin Alfa in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Elritercept
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Neoplasm malignant+1

Recruiting

Anti‑PD1 Therapy with pembrolizumab and cemiplimab in first‑line advanced non‑small cell lung cancer patients with high PD‑L1 expression

Registered drugNo placebo

Anti‑PD1 Therapy with pembrolizumab and cemiplimab in first‑line advanced non‑small cell lung cancer patients with high PD‑L1 expression

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:Unicancer

Contact Research Centre

Neoplasm

Recruiting

Safety and Preliminary Efficacy of Oral GSK5460025A Alone or with Drug Combination in Adult Patients with dMMR/MSI‑H Colorectal Cancer

InvestigationalNo placebo

Safety and Preliminary Efficacy of Oral GSK5460025A Alone or with Drug Combination in Adult Patients with dMMR/MSI‑H Colorectal Cancer

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:GSK5460025A
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Small cell lung cancer extensive stage

Recruiting

A study of PF-08634404 and a drug combination for adult patients with extensive-stage small cell lung cancer

Registered drugNo placebo

A study of PF-08634404 and a drug combination for adult patients with extensive-stage small cell lung cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Pfizer Inc.

Contact Research Centre

Non-small cell lung cancer

Recruiting

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Amgen Inc.

Contact Research Centre

Squamous cell carcinoma of lung+4

Recruiting

A study of PF-08634404 and a drug combination in adults with advanced or metastatic non-small cell lung cancer

Registered drug

A study of PF-08634404 and a drug combination in adults with advanced or metastatic non-small cell lung cancer

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Pfizer Inc.

Contact Research Centre

Endometrial cancer

Recruiting

A study of ACR-368 and gemcitabine for patients with endometrial cancer

Registered drugNo placebo

A study of ACR-368 and gemcitabine for patients with endometrial cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Gemcitabine
Sponsor:Acrivon Therapeutics Inc.

Contact Research Centre

Colorectal cancer metastatic

Recruiting

A Study Comparing PF-08634404 and a Drug Combination with Chemotherapy in Adults with Metastatic Colorectal Cancer

Registered drugNo placebo

A Study Comparing PF-08634404 and a Drug Combination with Chemotherapy in Adults with Metastatic Colorectal Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Pfizer Inc.

Contact Research Centre

Breast cancer

Recruiting

Study of inavolisib, ribociclib, and fulvestrant for patients with advanced hormone-receptor-positive, HER2-negative breast cancer.

Registered drug

Study of inavolisib, ribociclib, and fulvestrant for patients with advanced hormone-receptor-positive, HER2-negative breast cancer.

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Fulvestrant
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Neoplasm

Recruiting

A study of RPTR-1-201 and pembrolizumab in patients with advanced solid tumors

Registered drugNo placebo

A study of RPTR-1-201 and pembrolizumab in patients with advanced solid tumors

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Repertoire Immune Medicines Inc.

Contact Research Centre

Colorectal cancer metastatic

Recruiting

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Hormone-refractory prostate cancer

Recruiting

A study of JNJ-78278343 and docetaxel compared to docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo

A study of JNJ-78278343 and docetaxel compared to docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Docetaxel
Sponsor:Janssen Cilag International

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Villejuif

What the registry says about research in the country

01 Oncology - Head and Neck Cancer

Innovative research focusing on locally advanced head and neck squamous cell carcinoma treatments, including novel therapies combined with radiotherapy and immunotherapy approaches.

NBTXR3 with radiotherapy
EGFR-ADC therapy combinations
HPV-positive oropharyngeal cancer

02 Gastrointestinal Oncology

Studies targeting various digestive system cancers, with particular focus on pancreatic adenocarcinoma and advanced gastric cancer treatments.

Anti-CEACAM5 ADC therapy
Sotorasib combinations
Novel gastrointestinal cancer treatments

03 Hematologic Malignancies

Cutting-edge research in multiple myeloma treatment, exploring new combination therapies and maintenance approaches.

Elranatamab-lenalidomide therapy
Belantamab mafodotin combinations
T-cell lymphoma treatments

04 Lung Cancer Research

Comprehensive studies in both non-small cell lung cancer and small cell lung cancer, investigating targeted therapies and immunotherapy combinations.

Novel antibody-drug conjugates
Microbiome-based approaches
Targeted therapy combinations

05 Advanced Solid Tumors

Broad-spectrum research investigating novel treatments for metastatic solid tumors, including innovative therapeutic approaches and combination strategies.

PARG inhibitor studies
Targeted molecular therapies
Immunotherapy combinations

Back to France All countries